InVivo Therapeutics Holdings Corporation (NVIV)
Price:
0.32 USD
( - -0.17 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Fidelity Select Biotechnology Portfolio
VALUE SCORE:
6
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
NEWS
Why Is InVivo Therapeutics (NVIV) Stock Up 61% Today?
investorplace.com
2024-02-06 07:54:20InVivo Therapeutics (NASDAQ: NVIV ) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biomaterials and biotechnology company this morning. Instead, it looks like heavy trading of NVIV stock is behind today's movement.
Why Is InVivo Therapeutics (NVIV) Stock Down 34% Today?
investorplace.com
2022-10-07 10:25:51Source: ra2 studio/Shutterstock InVivo Therapeutics (NASDAQ: NVIV ) stock is on the move Friday after the company reached a deal for a direct offering of its shares. The registered direct offering has InVivo Therapeutics agreeing to sell 523,810 shares of NVIV stock to a single institutional investor.
7 Biotech Stocks to Buy That Have Millionaire-Maker Potential
investorplace.com
2021-09-10 12:19:36This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.
InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study
businesswire.com
2021-09-08 08:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has enrolled 15 patients with acute spinal cord injury into the INSPIRE 2.0 Study, or 75% of the total 20-patient enrollment target for the study. The INSPIRE 2.0 study is a randomized, controlled trial (20-patient, 10 subjects in each study arm), that is designed
3 Biotech Penny Stocks That You Need to Know About In 2021
pennystocks.com
2021-07-20 15:16:23Are these the best biotech penny stocks to watch in 2021? The post 3 Biotech Penny Stocks That You Need to Know About In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Penny Stocks To Watch For July 2021
pennystocks.com
2021-07-14 13:39:48Penny Stocks For Your Watch List In July The post Best Penny Stocks To Watch For July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
NVIV Stock Increases Over 36% Intraday: Why It Happened
pulse2.com
2021-07-13 15:43:49The stock price of Invivo Therapeutics Holdings Corp (NASDAQ: NVIV) increased by over 36% during intraday trading. This is why it happened.
InVivo Therapeutics Stock Moves Higher On FDA Acceptance Of Preclinical Module For Neuro-Spinal Implant
benzinga.com
2021-07-13 09:13:57The FDA has accepted InVivo Therapeutics Holdings Corp's (NASDAQ: NVIV) preclinical module, which is one of three individual modules required for the Company's humanitarian device exemption (HDE) application for its Neuro-Spinal Scaffold implant. Acceptance of the module indicates that FDA has completed its review of this module of the HDE and has no outstanding questions.
InVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021
businesswire.com
2021-07-06 08:05:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today reminded stockholders that their virtual Annual Meeting of Stockholders is scheduled for Friday, July 16, 2021 at 11 a.m., ET and called on stockholders to vote to ensure that a quorum is present to hold the meeting and that the Company's proxy proposals are passed. Stockholders hol
InVivo Therapeutics Announces Presentation at Upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
businesswire.com
2021-03-12 08:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference, which runs from March 17 – March 19 from 9:00 am – 5:00 pm ET. Dr. Toselli's presentation will provi
InVivo Therapeutics Announces Presentation at Upcoming 2021 H.C. Wainwright Global Life Sciences Conference
businesswire.com
2021-03-05 08:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming 2021 H.C. Wainwright Global Life Sciences Conference. The conference is scheduled to be held March 9-10, 2021 in a virtual format. Dr. Toselli's presentation will provide an ove
InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine
businesswire.com
2021-02-16 08:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the recent publication of a peer-reviewed manuscript in the Journal of Neurosurgery: Spine describing the previously presented complete six-month primary endpoint results from the company's single-arm INSPIRE 1.0 study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury), titled “A study of
SCI Adds Merchants Fleet to Growing Customer Offerings
einpresswire.com
2020-10-19 15:18:27SCI has launched a national fleet rental and leasing program for its Logistics Brokers that will enable business growth by reducing vehicle costs.
NYC teacher suspected of sexual relationship with student invokes Fifth Amendment
nypost.com
2020-10-18 01:35:20David Lado invoked the Fifth Amendment against self-incrimination when asked by city school investigators about his relationship with a female student, records show.
12 Healthcare Stocks Moving In Friday's After-Market Session
benzinga.com
2020-10-16 00:00:00Gainers InVivo Therapeutics Hldg (NASDAQ:NVIV) shares rose 11.11% to $1.5 during Friday's after-market session. InVivo Therapeutics Hldg's trading volume hit 1.4K shares...
ClearPoint Neuro: Becoming The World's Pre-Eminent Neurosurgery Platform (NASDAQ:CLPT)
seekingalpha.com
2020-10-14 13:30:2320 Gene Therapy Clinical Trials Using the ClearPoint platform. Utilizes Razor / Blades Business Model.
No data to display
Why Is InVivo Therapeutics (NVIV) Stock Up 61% Today?
investorplace.com
2024-02-06 07:54:20InVivo Therapeutics (NASDAQ: NVIV ) stock is rocketing higher on Tuesday despite a lack of news from the clinical-stage biomaterials and biotechnology company this morning. Instead, it looks like heavy trading of NVIV stock is behind today's movement.
Why Is InVivo Therapeutics (NVIV) Stock Down 34% Today?
investorplace.com
2022-10-07 10:25:51Source: ra2 studio/Shutterstock InVivo Therapeutics (NASDAQ: NVIV ) stock is on the move Friday after the company reached a deal for a direct offering of its shares. The registered direct offering has InVivo Therapeutics agreeing to sell 523,810 shares of NVIV stock to a single institutional investor.
7 Biotech Stocks to Buy That Have Millionaire-Maker Potential
investorplace.com
2021-09-10 12:19:36This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.
InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study
businesswire.com
2021-09-08 08:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has enrolled 15 patients with acute spinal cord injury into the INSPIRE 2.0 Study, or 75% of the total 20-patient enrollment target for the study. The INSPIRE 2.0 study is a randomized, controlled trial (20-patient, 10 subjects in each study arm), that is designed
3 Biotech Penny Stocks That You Need to Know About In 2021
pennystocks.com
2021-07-20 15:16:23Are these the best biotech penny stocks to watch in 2021? The post 3 Biotech Penny Stocks That You Need to Know About In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Penny Stocks To Watch For July 2021
pennystocks.com
2021-07-14 13:39:48Penny Stocks For Your Watch List In July The post Best Penny Stocks To Watch For July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
NVIV Stock Increases Over 36% Intraday: Why It Happened
pulse2.com
2021-07-13 15:43:49The stock price of Invivo Therapeutics Holdings Corp (NASDAQ: NVIV) increased by over 36% during intraday trading. This is why it happened.
InVivo Therapeutics Stock Moves Higher On FDA Acceptance Of Preclinical Module For Neuro-Spinal Implant
benzinga.com
2021-07-13 09:13:57The FDA has accepted InVivo Therapeutics Holdings Corp's (NASDAQ: NVIV) preclinical module, which is one of three individual modules required for the Company's humanitarian device exemption (HDE) application for its Neuro-Spinal Scaffold implant. Acceptance of the module indicates that FDA has completed its review of this module of the HDE and has no outstanding questions.
InVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021
businesswire.com
2021-07-06 08:05:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today reminded stockholders that their virtual Annual Meeting of Stockholders is scheduled for Friday, July 16, 2021 at 11 a.m., ET and called on stockholders to vote to ensure that a quorum is present to hold the meeting and that the Company's proxy proposals are passed. Stockholders hol
InVivo Therapeutics Announces Presentation at Upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
businesswire.com
2021-03-12 08:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference, which runs from March 17 – March 19 from 9:00 am – 5:00 pm ET. Dr. Toselli's presentation will provi
InVivo Therapeutics Announces Presentation at Upcoming 2021 H.C. Wainwright Global Life Sciences Conference
businesswire.com
2021-03-05 08:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming 2021 H.C. Wainwright Global Life Sciences Conference. The conference is scheduled to be held March 9-10, 2021 in a virtual format. Dr. Toselli's presentation will provide an ove
InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine
businesswire.com
2021-02-16 08:00:00CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the recent publication of a peer-reviewed manuscript in the Journal of Neurosurgery: Spine describing the previously presented complete six-month primary endpoint results from the company's single-arm INSPIRE 1.0 study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury), titled “A study of
SCI Adds Merchants Fleet to Growing Customer Offerings
einpresswire.com
2020-10-19 15:18:27SCI has launched a national fleet rental and leasing program for its Logistics Brokers that will enable business growth by reducing vehicle costs.
NYC teacher suspected of sexual relationship with student invokes Fifth Amendment
nypost.com
2020-10-18 01:35:20David Lado invoked the Fifth Amendment against self-incrimination when asked by city school investigators about his relationship with a female student, records show.
12 Healthcare Stocks Moving In Friday's After-Market Session
benzinga.com
2020-10-16 00:00:00Gainers InVivo Therapeutics Hldg (NASDAQ:NVIV) shares rose 11.11% to $1.5 during Friday's after-market session. InVivo Therapeutics Hldg's trading volume hit 1.4K shares...
ClearPoint Neuro: Becoming The World's Pre-Eminent Neurosurgery Platform (NASDAQ:CLPT)
seekingalpha.com
2020-10-14 13:30:2320 Gene Therapy Clinical Trials Using the ClearPoint platform. Utilizes Razor / Blades Business Model.